JP5801794B2 - カンナビジオールの製剤及びその使用方法 - Google Patents

カンナビジオールの製剤及びその使用方法 Download PDF

Info

Publication number
JP5801794B2
JP5801794B2 JP2012508657A JP2012508657A JP5801794B2 JP 5801794 B2 JP5801794 B2 JP 5801794B2 JP 2012508657 A JP2012508657 A JP 2012508657A JP 2012508657 A JP2012508657 A JP 2012508657A JP 5801794 B2 JP5801794 B2 JP 5801794B2
Authority
JP
Japan
Prior art keywords
composition
cannabidiol
gel
approximately
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012508657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525416A (ja
JP2012525416A5 (enExample
Inventor
リン スティンチクーム オードラ
リン スティンチクーム オードラ
リー バンクス スタン
リー バンクス スタン
Original Assignee
ジネルバ ファーマシューティカルズ， インコーポレイティド
ジネルバ ファーマシューティカルズ， インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジネルバ ファーマシューティカルズ， インコーポレイティド, ジネルバ ファーマシューティカルズ， インコーポレイティド filed Critical ジネルバ ファーマシューティカルズ， インコーポレイティド
Publication of JP2012525416A publication Critical patent/JP2012525416A/ja
Publication of JP2012525416A5 publication Critical patent/JP2012525416A5/ja
Application granted granted Critical
Publication of JP5801794B2 publication Critical patent/JP5801794B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
JP2012508657A 2009-04-28 2010-04-28 カンナビジオールの製剤及びその使用方法 Expired - Fee Related JP5801794B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17346909P 2009-04-28 2009-04-28
US61/173,469 2009-04-28
PCT/US2010/032822 WO2010127033A1 (en) 2009-04-28 2010-04-28 Formulations of cannabidiol and methods of using the same

Publications (3)

Publication Number Publication Date
JP2012525416A JP2012525416A (ja) 2012-10-22
JP2012525416A5 JP2012525416A5 (enExample) 2014-12-11
JP5801794B2 true JP5801794B2 (ja) 2015-10-28

Family

ID=42246015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012508657A Expired - Fee Related JP5801794B2 (ja) 2009-04-28 2010-04-28 カンナビジオールの製剤及びその使用方法

Country Status (6)

Country Link
US (1) US20100273895A1 (enExample)
EP (1) EP2424525A1 (enExample)
JP (1) JP5801794B2 (enExample)
CA (1) CA2760460C (enExample)
MX (1) MX2011011514A (enExample)
WO (1) WO2010127033A1 (enExample)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784336B2 (en) 2005-08-24 2014-07-22 C. R. Bard, Inc. Stylet apparatuses and methods of manufacture
US8388546B2 (en) 2006-10-23 2013-03-05 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
US7794407B2 (en) 2006-10-23 2010-09-14 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
US8849382B2 (en) 2007-11-26 2014-09-30 C. R. Bard, Inc. Apparatus and display methods relating to intravascular placement of a catheter
ES2465915T3 (es) 2007-11-26 2014-06-09 C.R. Bard, Inc. Sistema integrado para la colocación intravascular de un catéter
US9521961B2 (en) 2007-11-26 2016-12-20 C. R. Bard, Inc. Systems and methods for guiding a medical instrument
US9649048B2 (en) 2007-11-26 2017-05-16 C. R. Bard, Inc. Systems and methods for breaching a sterile field for intravascular placement of a catheter
US10449330B2 (en) 2007-11-26 2019-10-22 C. R. Bard, Inc. Magnetic element-equipped needle assemblies
US10751509B2 (en) 2007-11-26 2020-08-25 C. R. Bard, Inc. Iconic representations for guidance of an indwelling medical device
US9636031B2 (en) 2007-11-26 2017-05-02 C.R. Bard, Inc. Stylets for use with apparatus for intravascular placement of a catheter
US10524691B2 (en) 2007-11-26 2020-01-07 C. R. Bard, Inc. Needle assembly including an aligned magnetic element
US8781555B2 (en) 2007-11-26 2014-07-15 C. R. Bard, Inc. System for placement of a catheter including a signal-generating stylet
US8478382B2 (en) 2008-02-11 2013-07-02 C. R. Bard, Inc. Systems and methods for positioning a catheter
ES2525525T3 (es) 2008-08-22 2014-12-26 C.R. Bard, Inc. Conjunto de catéter que incluye conjuntos de sensor de ECG y magnético
US8437833B2 (en) 2008-10-07 2013-05-07 Bard Access Systems, Inc. Percutaneous magnetic gastrostomy
JP5795576B2 (ja) 2009-06-12 2015-10-14 バード・アクセス・システムズ，インコーポレーテッド 心電図（ｅｃｇ）信号を使用して心臓内またはその近くに血管内デバイスを位置決めするコンピュータベースの医療機器の作動方法
US9532724B2 (en) 2009-06-12 2017-01-03 Bard Access Systems, Inc. Apparatus and method for catheter navigation using endovascular energy mapping
WO2011019760A2 (en) 2009-08-10 2011-02-17 Romedex International Srl Devices and methods for endovascular electrography
US11103213B2 (en) 2009-10-08 2021-08-31 C. R. Bard, Inc. Spacers for use with an ultrasound probe
JP2013518676A (ja) 2010-02-02 2013-05-23 シー・アール・バード・インコーポレーテッド カテーテルナビゲーションおよびチップの位置を特定するための装置および方法
ES2929130T3 (es) 2010-05-28 2022-11-25 Bard Inc C R Sistema de guiado de inserción para agujas y componente médicos
EP2912999B1 (en) 2010-05-28 2022-06-29 C. R. Bard, Inc. Apparatus for use with needle insertion guidance system
CA2806353A1 (en) 2010-08-09 2012-02-16 C.R. Bard Inc. Support and cover structures for an ultrasound probe head
CN103442632A (zh) 2010-08-20 2013-12-11 C·R·巴德股份有限公司 Ecg辅助导管末端放置的再确认
ES2541485T3 (es) * 2010-10-19 2015-07-21 Parenteral, A.S. Composición para el tratamiento de enfermedades inflamatorias, la cual comprende ácidos boswéllicos y cannabidiol
US8801693B2 (en) 2010-10-29 2014-08-12 C. R. Bard, Inc. Bioimpedance-assisted placement of a medical device
US11344505B1 (en) * 2010-12-01 2022-05-31 Gowey Research Group, Pllc Herbal formulations of carnivorous plants and methods for treating inflammation
US12318420B2 (en) 2010-12-01 2025-06-03 Gowey Research Group, Pllc Herbal formulations of carnivorous plants and methods for treating inflammation
US9566341B1 (en) 2011-04-27 2017-02-14 University Of Kentucky Research Foundation Compounds including Cox inhibitor moiety and enhanced delivery of active drugs using same
WO2013006817A1 (en) 2011-07-06 2013-01-10 C.R. Bard, Inc. Needle length determination and calibration for insertion guidance system
USD699359S1 (en) 2011-08-09 2014-02-11 C. R. Bard, Inc. Ultrasound probe head
USD724745S1 (en) 2011-08-09 2015-03-17 C. R. Bard, Inc. Cap for an ultrasound probe
JP5820206B2 (ja) 2011-09-13 2015-11-24 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
JP5820207B2 (ja) * 2011-09-13 2015-11-24 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
WO2013070775A1 (en) 2011-11-07 2013-05-16 C.R. Bard, Inc Ruggedized ultrasound hydrogel insert
EP2861153A4 (en) 2012-06-15 2016-10-19 Bard Inc C R APPARATUS AND METHODS FOR DETECTION OF A REMOVABLE CAP ON AN ULTRASONIC PROBE
WO2014159688A1 (en) * 2013-03-14 2014-10-02 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
ES2538335T3 (es) * 2013-05-14 2015-06-19 Najöpharm Gmbh I.G. Combinación de ácido poliacrílico y 2-amino-2-metilpropanol para uso en el tratamiento de infecciones por herpes
WO2016187722A1 (en) * 2015-05-27 2016-12-01 Mary Lynch Use of cannabinoids in the treatment of ocular inflammation and/or pain
CA2931039C (en) 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
US9839372B2 (en) 2014-02-06 2017-12-12 C. R. Bard, Inc. Systems and methods for guidance and placement of an intravascular device
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
EP3177286A4 (en) * 2014-07-18 2018-05-16 Medipath Inc. Compositions and methods for physiological delivery using cannabidiol
EP3171872B1 (en) * 2014-07-21 2020-11-11 Glia, LLC Method for treating radiotherapy-and-chemotherapy associated cognitive or emotional impairment with cannabinoids
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10398776B1 (en) * 2014-11-03 2019-09-03 Essential Green Goodness LLC Phonophoretic cannabidiol composition and transdermal delivery system
WO2016098112A1 (en) * 2014-12-17 2016-06-23 One World Cannabis Ltd Novel condom comprising cannabis derived compositions for enhancement of sexual pleasure and decrease of erectile dysfunction symptoms
DK3232808T3 (da) * 2014-12-19 2020-06-02 Thc Pharm Gmbh The Health Concept CBD-holdig drik
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
US10973584B2 (en) 2015-01-19 2021-04-13 Bard Access Systems, Inc. Device and method for vascular access
CN107530318A (zh) * 2015-03-02 2018-01-02 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
EP4193990A1 (en) * 2015-05-28 2023-06-14 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2016210325A1 (en) 2015-06-26 2016-12-29 C.R. Bard, Inc. Connector interface for ecg-based catheter positioning system
GB2542797A (en) * 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
GB2544468A (en) * 2015-11-12 2017-05-24 Jaytee Biosciences Ltd Liquid formulation
US11000207B2 (en) 2016-01-29 2021-05-11 C. R. Bard, Inc. Multiple coil system for tracking a medical device
MX382853B (es) 2016-04-22 2025-03-13 Spoke Sciences Inc Compuestos medicinales y suplementos nutricionales de base vegetal de rápida acción.
US20190184364A1 (en) * 2016-05-03 2019-06-20 International Flavors & Fragrances Inc. Fragrance compositions containing microcapsules
AU2017260706B2 (en) 2016-05-04 2023-05-11 Inmed Pharmaceuticals Inc. Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
US20190030170A1 (en) * 2016-05-10 2019-01-31 Vireo Health LLC Cannabinoid formulations with improved solubility
CN109963595B (zh) 2016-10-11 2023-02-03 Gbs全球生物制药公司 用于治疗神经退行性疾病的含有大麻素的复合混合物
EP3534893A1 (en) * 2016-11-02 2019-09-11 To Pharmaceuticals LLC Combination therapy of cbd and copaxone
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
WO2018144637A1 (en) 2017-02-01 2018-08-09 Growblox Life Sciences L.L.C. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
IL268728B2 (en) * 2017-02-15 2024-09-01 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of acne
US10231948B2 (en) 2017-02-27 2019-03-19 Jason Ty Nguyen Metered dose inhaler compositions, systems, and methods
GB201706969D0 (en) * 2017-05-02 2017-06-14 Medherant Ltd Formulation
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
US20190022028A1 (en) * 2017-07-21 2019-01-24 Annabelle Manalo Cannabidiol-enriched caprylic acid
CA3071497A1 (en) * 2017-08-13 2019-02-21 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition and method of treatment
IL301622A (en) * 2017-08-14 2023-05-01 Zynerba Pharmaceuticals Inc Methods of treatment of osteoarthritis with transdermal cannabidiol gel
CN109498606A (zh) * 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
US20190083388A1 (en) 2017-09-19 2019-03-21 Zynerba Pharmaceuticals, Inc. Synthentic transdermal cannabidiol for the treatment of focal epilepsy in adults
US12357604B2 (en) 2017-09-22 2025-07-15 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
US10220061B1 (en) 2017-09-26 2019-03-05 Cynthia Denapoli Method of reducing stress and anxiety in equines
US10213390B1 (en) * 2017-09-28 2019-02-26 Zynerba Pharmaceuticals, Inc. Treatment of fragile X syndrome with cannabidiol
CN118203735A (zh) 2017-10-04 2024-06-18 精呼吸股份有限公司 电子呼吸致动式直线型液滴输送装置及其使用方法
WO2019079402A2 (en) * 2017-10-17 2019-04-25 Life Tech Global, Llc IMPROVED ADMINISTRATION SYSTEMS FOR FRACTIONS COMPRISING ENHANCED COMBINATIONS OF CBD, FORMULATIONS AND CHIMERS
JP2021502178A (ja) 2017-11-08 2021-01-28 ニューマ・リスパイラトリー・インコーポレイテッド 小容積アンプルを有して呼吸により電気的に作動するインライン液滴送達装置および使用方法
KR102063524B1 (ko) * 2017-11-10 2020-01-08 안용훈 칸나비디올을 포함하는 화장료 조성물
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201720992D0 (en) * 2017-12-15 2018-01-31 Hooper Mark A medical use
US20210052492A1 (en) * 2018-01-24 2021-02-25 Botanix Pharmaceuticals Ltd. Cannabinoid Dosing Regime For Psoriasis
BR112020014911A2 (pt) * 2018-01-24 2020-12-08 Botanix Pharmaceuticals Ltd Regime de dosagem de canabinoide para dermatite e condições de pele inflamatórias
CN112020352A (zh) * 2018-01-24 2020-12-01 博塔尼克斯制药有限公司 用于痤疮的大麻素给药方案
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
MX2020011371A (es) * 2018-04-27 2021-04-12 Remy Biosciences Inc Nuevos dispositivos medicos, vehiculos de suministro y fabricacion de los mismos.
US11096904B2 (en) 2018-05-11 2021-08-24 Linda J. Kaplan Methods and nutraceutical compositions for the prevention and/or mitigation of veisalgia
US20200009078A1 (en) * 2018-07-03 2020-01-09 TRUETIVA, Inc. Oral compositions
US10588979B1 (en) * 2018-09-17 2020-03-17 Cody D. Freeze Cannabinoid and terpene-infused topical cream
EP3852622B1 (en) 2018-10-16 2025-04-02 Bard Access Systems, Inc. Safety-equipped connection systems and methods thereof for establishing electrical connections
AU2019385420A1 (en) 2018-11-19 2021-07-08 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
MX2021007076A (es) 2018-12-14 2021-08-11 Zynerba Pharmaceuticals Inc Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
JP2022512409A (ja) 2018-12-14 2022-02-03 ナチュラル イクストゥラクション システムズ，エルエルシー アニオン性カンナビノイド分子と関連する組成物および方法
US20220071922A1 (en) * 2018-12-26 2022-03-10 Clear Lake Research, Llc Delivery of health benefits through component formulation
CN113544117A (zh) * 2019-02-06 2021-10-22 埃默拉尔德健康制药公司 大麻二酚衍生物的调配物和其作为2型大麻素受体（cb２）的调节剂的用途
IT201900003325A1 (it) * 2019-03-07 2020-09-07 C I A M S R L Composizione per la prevenzione e trattamento della dermatite atopica
US20230414492A1 (en) * 2019-04-02 2023-12-28 Nose To Brain Therapeutics Llc Intranasal delivery of cannabidiol to treat central nervous system disorders
WO2020206205A1 (en) * 2019-04-03 2020-10-08 Willow Bark Brands, Inc Dosage forms and methods of preparation and use thereof
US11806645B1 (en) 2019-05-07 2023-11-07 Cannaceutical Extractions LLC Methods of producing CBD/THC oils
US12029707B2 (en) 2019-05-28 2024-07-09 Tech Swerve Llc Penetrating topical pain relief compositions and methods of use
CA3141993A1 (en) 2019-05-28 2020-12-03 Tech Swerve Llc Penetrating topical pain relief compositions and methods of use
US11931333B1 (en) * 2019-05-28 2024-03-19 Peter Van Horn Topical treatment of herpes infections
EP3986395A4 (en) * 2019-06-18 2023-08-09 Botanix Pharmaceuticals Ltd ANTIBACTERIAL DOSAGE REGIMEN USING CANNABINOIDS
WO2021023351A1 (en) * 2019-08-05 2021-02-11 Cs Group Aps Topical formulations comprising cannabidiol, method of preparing the composition and use thereof
WO2021042001A1 (en) * 2019-08-30 2021-03-04 Natural Extraction Systems, LLC Compositions and methods related to dissolved oxides
WO2021051105A2 (en) 2019-09-12 2021-03-18 Nulixir Inc. Controlled release core-shell particles and suspensions including the same
JOP20220054A1 (ar) 2019-09-17 2023-01-30 Zynerba Pharmaceuticals Inc علاج اعتلال الدماغ syngap1
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) * 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
WO2021070120A1 (en) * 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
JP2022551002A (ja) 2019-10-13 2022-12-06 フィジーン、エルエルシー 椎間板変性疾患の治療のためのカンナビジオール補助療法
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12097293B2 (en) 2019-10-14 2024-09-24 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US20220387351A1 (en) * 2019-10-31 2022-12-08 Natural Extraction Systems, LLC Compositions and Methods Related to Organic Oxides
CA3166011A1 (en) * 2019-12-31 2021-07-08 Soluscience, Llc Water-soluble cannabinoid formulations and methods of their making
WO2021150595A1 (en) * 2020-01-20 2021-07-29 Nutramax Laboratories, Inc. Novel formulations comprising cannabis
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
WO2021214545A1 (en) * 2020-04-20 2021-10-28 Pike Therapeutics, Inc. Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain
US11998514B2 (en) 2020-05-21 2024-06-04 Elementis Specialties, Inc. Cannabidiol and active delivery systems
JP2023528354A (ja) 2020-05-26 2023-07-04 ジナーバ・ファーマシューティカルズ・インコーポレイテッド カンナビジオールを用いた自閉症スペクトラム障害の処置
EP4171528A1 (en) 2020-06-29 2023-05-03 Zynerba Pharmaceuticals, Inc. Treatment of fragile x syndrome with cannabidiol
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
US20230131989A1 (en) * 2020-07-29 2023-04-27 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders
US12349706B2 (en) 2020-07-31 2025-07-08 Natural Extraction Systems, LLC Compositions and methods related to excipients and cannabinoid formulations
GB202012836D0 (en) * 2020-08-17 2020-09-30 Futura Medical Developments Ltd Topical composition
WO2022038218A1 (en) * 2020-08-21 2022-02-24 Unilever Ip Holdings B.V. Preservative systems and compositions comprising the same
WO2022104245A2 (en) 2020-11-16 2022-05-19 SYNERGY LIFE SCIENCE, Inc. Cannabinoid emulsifier
AU2021393122A1 (en) * 2020-12-03 2023-06-29 Pike Therapeutics Inc. Transdermal pharmaceutical formulations comprising cbd or thc for the treatment of cancer
CA3200996A1 (en) 2020-12-03 2022-06-09 Joseph Palumbo Treatment of refractory seizures
CA3206508A1 (en) 2021-01-28 2022-08-04 Joseph Palumbo Treatment of sleep apnea with cbd
WO2022167652A1 (en) 2021-02-05 2022-08-11 Cs Medica A/S Supplement for arthritis and psoriasis
JP2024514843A (ja) * 2021-04-08 2024-04-03 パイク セラピューティクス インコーポレイテッド 発作性疾患を治療するための医薬組成物及び方法
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
MX2023012483A (es) * 2021-04-22 2023-11-03 Pike Therapeutics Inc Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico.
DK181458B1 (en) * 2021-05-06 2024-01-31 Cs Medica As Wound treatment composition, use thereof and method for providing said composition
DK181405B1 (en) 2021-05-25 2023-10-17 Cs Medica As Gel for Intranasal Application, its Provision and Use
JP2024525200A (ja) 2021-06-22 2024-07-10 ニューマ・リスパイラトリー・インコーポレイテッド プッシュ排出を用いる液滴送達デバイス
US12064461B2 (en) * 2021-07-16 2024-08-20 Avicanna Inc. Deep penetrating topical cannabinoid compositions and methods for treating musculoskeletal inflammation and pain
US20250228876A1 (en) * 2021-10-13 2025-07-17 Pneuma Respiratory, Inc. Compositions for delivery of cannabinoids
WO2023070045A1 (en) 2021-10-22 2023-04-27 Zynerba Pharmaceuticals, Inc. Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance
KR20240122436A (ko) 2021-10-26 2024-08-12 에코파이버 유에스에이 인코포레이티드 대마 추출물을 생성하기 위한 시스템 및 방법과 조성물
IL312245A (en) 2021-10-26 2024-06-01 Ecofibre Usa Inc Methods of treating endometriosis and other non-cancer gynecological disorders with hemp extract
WO2023076928A1 (en) 2021-10-26 2023-05-04 Ecofibre Limited Methods of treating ovarian cancer with hemp extract
US20230404910A1 (en) * 2022-06-16 2023-12-21 Stephanie Gore Implantable cannabis transdermal
CN119768202A (zh) 2022-07-18 2025-04-04 精呼吸股份有限公司 小步长高分辨率气溶胶生成系统及方法
US12097211B2 (en) 2022-10-26 2024-09-24 Ecofibre USA Inc. Methods of treating estrogen sensitive diseases with cannabis extract
EP4608426A1 (en) 2022-10-26 2025-09-03 Ecofibre USA Inc. Stabilized compositions comprising cannabidiol
WO2024158861A1 (en) * 2023-01-24 2024-08-02 Actual Natural Health & Wellness Products, Inc. Nasal hygiene method and composition
WO2024234014A1 (en) * 2023-05-11 2024-11-14 Spiritus Bioscience, Inc. Sublingual spray formulations of psychedelics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
JP2010535238A (ja) * 2007-07-30 2010-11-18 オールトランツ インコーポレイティド カンナビジオールのプロドラッグ、カンナビジオールのプロドラッグを含む組成物及びその使用方法
WO2009020666A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use

Also Published As

Publication number Publication date
MX2011011514A (es) 2011-11-18
US20100273895A1 (en) 2010-10-28
WO2010127033A1 (en) 2010-11-04
CA2760460A1 (en) 2010-11-04
CA2760460C (en) 2019-04-02
JP2012525416A (ja) 2012-10-22
EP2424525A1 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
JP5801794B2 (ja) カンナビジオールの製剤及びその使用方法
US20240083866A1 (en) Prodrugs of tetrahydrocannabinol compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
DK2473475T3 (en) APPLICATION OF CANNABIDIOL PRODUCTS IN TOPIC AND TRANSDERMAL MICROWAVE ADMINISTRATION
DK2176208T3 (en) Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
US20120202891A1 (en) Cannabinoid-Containing Compositions and Methods for Their Use
EP3363439A2 (en) Therapeutic compositions for diabetic symmetrical polyneuropathy
HK1219733B (en) Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140820

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141021

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20141021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150611

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150827

R150 Certificate of patent or registration of utility model

Ref document number: 5801794

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees